SVNS
NEUTRALSolvonis Therapeutics to Acquire Awakn Life Sciences
The biotechnology company is acquiring Awakn Life Sciences, a firm developing therapeutics for addiction, in a deal valued at approximately £4.98 million.
Solvonis Therapeutics
0.1650GBX
13.79%
Market Cap
3.87M
Volume
26.02M
351% of avg
P/E Ratio
EPS (TTM)
Beta
1.62
Day Range
0.1490p - 0.1695p
52 Week Range
0.1000p0.1650p1.4070p
0.1650p
Upcoming Events
SVNS
BADSolvonis Therapeutics Reports Zero Revenue as It Pivots to Mental Health Therapeutics
The therapeutics developer reported zero revenue as it transitions to mental health treatments. Despite reduced losses, material uncertainties remain regarding going concern and future funding needs.
SVNS
NEUTRALSolvonis Therapeutics Announces Posting of Circular and Notice of General Meeting
The biotechnology company announces posting of a circular and notice of a general meeting to seek shareholder approval for the proposed acquisition and fundraising.
SVNS
NEUTRALSolvonis Therapeutics Announces Holding Change
The specialty industrial machinery company has announced a change in shareholding, with Spreadex LTD increasing its stake to 7.12%.
SVNS
NEUTRALSolvonis Therapeutics Engages PharmaVentures to Advise on Commercialisation of Mental Health Assets
The biotechnology company has engaged a transaction advisory firm to support the commercialisation of two clinical-stage programmes targeting the treatment of Alcohol Use Disorder.
SVNS
NEUTRALSolvonis Therapeutics Provides Update on European Patent Application
The biotechnology company provides an update on the progress of its European patent application for a mental health treatment program.
SVNS
NEUTRALSolvonis Therapeutics Provides Update on AWKN-SDN-14 Programme
The biotechnology company provides an update on the development of its AWKN-SDN-14 programme, including the appointment of Evotec to conduct preclinical testing.
SVNS
NEUTRALSolvonis Therapeutics Announces Change in Major Shareholding
The company has announced a change in major shareholding, with a director acquiring a 5.11% stake.
SVNS
GOODSolvonis Therapeutics Appoints Pharmaceutical Industry Veteran to Board
The biotechnology company has appointed a pharmaceutical industry veteran with over 40 years of experience to its board of directors, strengthening its expertise in drug development and commercialization.
SVNS
NEUTRALSolvonis Therapeutics to Present at PharmaSynergyRx Event
The biotechnology company will be presenting at an industry event, creating a platform for potential partnerships and deals.